To analyze the fi nancial impact of medicine procurement with the required bioavailability and or bioequivalence tests for the basic pharmaceutical services component.
INTRODUCTION
Although decentralization of health services in the public sector began in 1990, until 1997 the process to procure medicines followed a centralized management model, performed by the Medications Center (CEME). The termination of this body in connection with the National Medications Policy published in 1998 6 reinforced the decentralization policy proposed by the Sistema Único de Saúde (SUS -National Unifi ed Health System) and transferred management 9 of pharmaceutical services to municipalities. According to Kornis 6 management and fi nancing problems combined with sourcing logistics became great challenges in pharmaceutical services.
Procurement of medications in the public sector is performed through a bidding process, with competition between participants. Considering the fi nite resources, the challenge for public sector managers is to plan the medicines procurement process so that product quality in not diminished by the need to save money.
Besides transferring responsibility for performing medicines procurement to states and municipalities, the National Medicines Policy 6 has also adopted the registration and use of generic medicines as a priority.
Generic medications are defi ned as products similar to the innovator medicines, which are interchangeable and designated by the Brazilian Nonproprietary Name (BNN) and the International Nonproprietary Name (INN).
a They are usually produced after the expiration or renunciation of patent protection or other exclusivity right, once effi cacy, safety and quality are proven.
The Generic Medicines Policy (GMP) has been considered both nationally and internationally as a strategy to decrease costs and promote access to medicines. 3, 4, 5, 16 In Brazil, the substitutability of the innovator medicine with generic medications is assured by pharmaceutical equivalence and bioequivalence tests performed by laboratories credentialed by the Agênica Nacional de Vigilância Sanitária (ANVISA -National Health Surveillance Agency). Quality is assured by monitoring production facilities as well as through GMP, in accordance with RDC No. 210/ANVISA 12 ANVISA requires evidence of therapeutic equivalence of all oral medication prescribed by doctors, through demonstration of bioequivalence through relative bioavailability tests in vivo. For non-oral medications and non-prescription oral medications, therapeutic equivalence is proven by in vitro test for pharmaceutical equivalence. 13 A study evaluating regulatory trends of generic medications in 14 Latin American and Caribbean countries described the most common regulatory aspects of generic medication policy. It is mandatory to use the INN on labels (in 13 of 14 countries), make public sector prescriptions with the INN (12 of 14) and undertake public sector procurement processes with the INN (11 of 14) . 15 Brazil fulfi lls these criteria and also establishes preference for generic medicines in public purchases, when prices and other procurement conditions are equal, and requires ANVISA to periodically edit the list of generics registered in the country.
Nonetheless, these measures appear insuffi cient to guarantee the availability of generics in public facilities, since usually brand name similar medicines are acquired rather than the generic or innovator medicines. According to a study by Miranda et al, in different regions of Brazil, only 25% of medications available in the public services studied were generic.
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Different explanations for the predominance of the brand name similar medicines in public purchases may include problems in fulfi lling the legislation, lack of interest by generic providers to participate in public purchases and offer of better prices for brand name similar medications. 13 What differentiates the generics from the brand name similar medicines is bioequivalence with the innovator medicines and not good manufacturing practices or intrinsic quality, which are required for all medications. 6 The brand name similar medicines existed before the Generics Law and are copies, which beginning in May 2003 should assimilate as generics by presenting the same tests when renewing registration. 6 Therefore, medications produced from November 2009 should prove pharmaceutical equivalence (in vitro test), and antibiotics, antineoplastic, and oral antiretrovirals should pass a relative bioavailability test (in vivo). By October 2014, all additional oral use therapeutic medicines classes will have passed the same tests. 13 Even given these changes, similar medications are viewed with skepticism by managers, health professionals and patients. Studies performed in Brazil show quality problems in part of these medications. Batistic et al 1 compiled data on physical analysis and quality of ferrous sulfate pills and oral solutions over a period of four years and found 37% of samples discordant with quality specifi cations, including labeling nonconformity, grade of the principal active ingredient (above or below declared), average weight, cracks in the pills and presence of precipitate in solutions. Another study 2 evaluated the quality of 10 mg enalapril and 40mg propranolol pills procured by a bidding process and distributed in the public health network of a municipality in Santa Catarina state, Southern Brazil, for a one year period, and found that fi ve of seven lots had quality problems.
In the municipality investigated, in 2008, following extensive discussion between managers and health professionals about the National Medicines Policy, the National Pharmaceutical Services Policy, the National Generics Policy and in spite of doubts of the quality of brand name similar medicines, a procurement of medicines occurred, which required that products had tests for bioequivalence and/or bioavailability. The study aimed to analyze the fi nancial impact of medicines procurement with the requirement of bioavailability and/or bioequivalence tests for the basic pharmaceutical services component. The Pharmaceutical Services coordinators participated in the development of the solicitation, technical analysis of proposals and medication receipt. The legal and fi nancial requirements of the bidding, as well as the execution of the auction were the responsibility of purchasing sector of the Municipal Health Secretary, together with the sector responsible for bidding in the Municipal Administration Secretary. The schedule for medicine procurement was made for 12 months, and the bidding process performed in the fi rst trimester. When the solicited items could not be procured, a new bidding process was undertaken, and this was repeated until all items were acquired.
The year 2007 was chosen because medicine procurement was performed without the bioavailability and/ or bioequivalence tests required in 2008, and both years were compared. Analysis included number of bids made by providers, number of annual bidding processes necessary to acquire all standard medicines, time to fi nalize the bidding process, the proportion of uncounted (failed) items, per unit cost and total value of procurement.
Per unit cost of medicines and quantity acquired were collected. The proportion of items that increased and decreased in cost and the average percent differences were determined from the difference in per unit cost of each medication procured in the two years of analysis.
The total fi nancial impact of generic procurement was evaluated through projected average annual consumption and per unit cost of each medication in the years analyzed. When more than one bidding process was used to procure the same medication, the per unit cost was calculated by averaging the values. Non-generic medicines procured in 2008 were excluded from analysis. (Table) . After failing in two procurement attempts in 2008, with the requirement of generics, the Health Department opted for procurement without the generics requirement in order to not compromise medicine availability. It took seven months to fi nalize the auction process on both years.
Even before the fi rst auction in 2008, a pharmaceutical laboratory offi cially registered opposition to the rules and requested reconsideration of the requirement to present bioavailability and bioequivalence tests, and this was the only request related to the technical requirements described in the acts for auction. 
DISCUSSION
The distinction between the two periods was the requirement of bioavailability and/or bioequivalence tests. This requirement was responsible for differences in the number of procurement attempts, bidding processes, failed items, per unit cost and total value to procure the medicines.
The technical requirement to present the bioavailability and/or bioequivalence tests may be contested, which can make the process even slower, but does not disrespect the principles of public auctions. Due to the high percentage of failed items in the fi rst and second bids of 2008, a third bidding process was necessary for which the bioavailability and/or bioequivalence tests were not required due to the possibility of stock-outs in the health system.
The amount of time to fi nalize the auction process was the same in both years. Although, in 2007, approximately 98% of items obtained price registration in the fi rst auction process, while approximately 25% of items in 2008 only were price registered during the last auction process. An increased number of items in the fi rst auction process is important to guarantee the supply of medicines, avoiding stock-outs in health units. The number of items missing and the duration of stock-out could not be estimated, since they are not registered in the system to manage supply.
The selection of the municipal medicines report was based on the Relação Nacional de Medicamentos Essenciais (RENAME -National List of Essential Medicines), with 70% of items standardized in the list. Nonetheless, the lack of quotes for generic medication in the auction process was notable and can be explained by the characteristics of the generics market. The difference between the unit price of medicines procured in 2007 and 2008 is signifi cant. Even though 44 items had decreased costs, the overall impact of requiring the bioavailability and/or bioequivalence tests in procurement was an increase of more than two million reais in 2008 for the municipality. The increase is related to the fact that generic medicines are usually cheaper than the innovator medicines but, in most cases, more expensive to the brand name similar medicines.
Generic medicines tend to be cheaper than the innovator medicines, in large part, because they do not consider the costs of development and clinical trials. Another factor that contributes to the cheaper price of the generic is the lower investment in marketing to increase brand recognition. 7 In Brazil, a study 16 demonstrated that generics were introduced with prices 40% lower on average than the innovator medicine, with a trend towards increases differences over time. The demand for generic medicines has not caused a reduction in prices of the majority of innovator medicines. A similar result was described in Canada. 7 This suggests that market loss to generics was insuffi cient to force an approximation in prices. 16 Although generics policy is highlighted as a way to reduce prices, this is only true if comparing generics and the innovator medicines. Brand name similar medicines are sold in Brazil for lower prices than generics, especially in public auctions, so that generics are uncompetitive in terms of price. Since the auctions are decided by the lowest price, the cost of medicines explains the low percentage of generics available in the public sector.
Analysis of the auction processes to procure medicines during the study period did not allow for estimation of the proportion of innovator, generic and brand name similar medicines procured in 2007. This is because the processes used the BNN, and there is no record of the manufacturing laboratory and the commercial name of the medication in the offi cial record, which are only available in the proposal by the company The information system to manage stocks also does not have this information available.
The production of two public edicts with different specifi cations may reduce the fi nancial impact caused by procurement of generic medications without interfering in the quality of the procured medicines. Bioavailability tests are necessary for solid and oral suspension medicines, be they generic or innovator medicines. For parenteral and oral solution medicines, this requirement is not necessary, as long as the dilution profi le does not signifi cantly interfere with the therapeutic result. If this strategy was adopted by the municipality studied, approximately 10% of the increased costs could be avoided by the municipality (about R$ 400,000).
Generic medicines policy is an important component for the management of pharmaceutical services, but it is still removed from the reality of the public health system. Tobar 14 reports that the most radical strategy to increase the supply of generic products is to allow generics to be used for all products registered in the country, as Argentina did in 2002: generics and brand name similar medicines were leveled and could compete for price. In Brazil, the new legislation for brand name similar medicines and innovator medicines required them to have the same quality standards of generics.
b,c Perhaps this is the fi rst step to incentivize price competitions between brand name similar medicines and generics and to increase their availability in public services.
In conclusion, municipal management adopted the policy to make medicines available that had presented bioavailability and bioequivalence tests to guarantee the provision of more effective and safe medications for the population. Nonetheless, procurement of these medicines had a large fi nancial impact, with an increase of almost 100%. Given fi nite fi nancial resources for health, the implementation of new health policies should be rationally planned, based on technical criteria and evaluation of the fi nancial impact from implementation. 
